​

NeuroBo Pharmaceuticals Stock (NASDAQ:NRBO)

RevenueOwnershipFinancialsChart

Previous Close

$2.35

52W Range

$2.04 - $6.75

50D Avg

$2.59

200D Avg

$3.63

Market Cap

$20.33M

Avg Vol (3M)

$42.68K

Beta

-0.28

Div Yield

-

NRBO Company Profile

NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company provides therapies for neurodegenerative, infectious, and cardiometabolic diseases. Its therapeutics programs include ANA001, an oral niclosamide formulation, which is in Phase 2/3 clinical trials to treat patients with moderate coronavirus disease (COVID-19); NB-01 for the treatment of painful diabetic neuropathy; NB-02 to treat the symptoms of cognitive impairment and modify the progression of neurodegenerative diseases associated with the malfunction of tau protein; and Gemcabene, an acute indication for COVID-19. NeuroBo Pharmaceuticals, Inc. is headquartered in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

8

IPO Date

Aug 05, 2016

Website

NRBO Performance

NRBO Financial Summary

Dec 23Dec 22Dec 21
Revenue$7.00K--
Operating Income$-15.89M$-19.63M$-15.30M
Net Income$-12.47M$-6.12M$-15.22M
EBITDA$-15.88M$-11.50M$-15.30M
Basic EPS$-2.46$-2.38$-19.73
Diluted EPS$-2.46$-2.38$-19.73

Fiscal year ends in Dec 23 | Currency in USD

Peer Comparison

TickerCompany
KPRXKiora Pharmaceuticals, Inc.
PHIOPhio Pharmaceuticals Corp.
REVBRevelation Biosciences, Inc.
BDRXBiodexa Pharmaceuticals Plc
QNRXQuoin Pharmaceuticals, Ltd.
VRAXVirax Biolabs Group Limited
ALLRAllarity Therapeutics, Inc.
ZURAZura Bio Limited
SONNSonnet BioTherapeutics Holdings, Inc.
CDIOCardio Diagnostics Holdings, Inc.
ATNF180 Life Sciences Corp.